T cells redirected to EphA2 for the immunotherapy of glioblastoma

Kevin KH Chow, Swati Naik, Sunitha Kakarla, Vita S. Brawley, Donald R. Shaffer, Zhongzhen Yi, Nino Rainusso, Meng Fen Wu, Hao Liu, Yvonne Kew, Robert G. Grossman, Suzanne Powell, Dean Lee, Nabil Ahmed, Stephen Gottschalk

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Outcomes for patients with glioblastoma (GBM) remain poor despite aggressive multimodal therapy. Immunotherapy with genetically modified T cells expressing chimeric antigen receptors (CARs) targeting interleukin (IL)-13Rα2, epidermal growth factor receptor variant III (EGFRvIII), or human epidermal growth factor receptor 2 (HER2) has shown promise for the treatment of gliomas in preclinical models and in a clinical study (IL-13Rα2). However, targeting IL-13Rα2 and EGFRvIII is associated with the development of antigen loss variants, and there are safety concerns with targeting HER2. Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype. To generate EphA2-specific T cells, we constructed an EphA2-specific CAR with a CD28-ζ endodomain. EphA2-specific T cells recognized EphA2-positive glioma cells as judged by interferon-γ (IFN-γ) and IL-2 production and tumor cell killing. In addition, EphA2-specific T cells had potent activity against human glioma-initiating cells preventing neurosphere formation and destroying intact neurospheres in coculture assays. Adoptive transfer of EphA2-specific T cells resulted in the regression of glioma xenografts in severe combined immunodeficiency (SCID) mice and a significant survival advantage in comparison to untreated mice and mice treated with nontransduced T cells. Thus, EphA2-specific T-cell immunotherapy may be a promising approach for the treatment of EphA2-positive GBM.

Original languageEnglish (US)
Pages (from-to)629-637
Number of pages9
JournalMolecular Therapy
Volume21
Issue number3
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Glioblastoma
Erythropoietin
varespladib methyl
Immunotherapy
Hepatocellular Carcinoma
T-Lymphocytes
Glioma
Interleukins
Antigen Receptors
Epidermal Growth Factor Receptor
Severe Combined Immunodeficiency
Adoptive Transfer
Coculture Techniques
Heterografts
Human Activities
Interferons
Interleukin-2
Therapeutics
Phenotype
Safety

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Chow, K. KH., Naik, S., Kakarla, S., Brawley, V. S., Shaffer, D. R., Yi, Z., ... Gottschalk, S. (2013). T cells redirected to EphA2 for the immunotherapy of glioblastoma. Molecular Therapy, 21(3), 629-637. https://doi.org/10.1038/mt.2012.210

T cells redirected to EphA2 for the immunotherapy of glioblastoma. / Chow, Kevin KH; Naik, Swati; Kakarla, Sunitha; Brawley, Vita S.; Shaffer, Donald R.; Yi, Zhongzhen; Rainusso, Nino; Wu, Meng Fen; Liu, Hao; Kew, Yvonne; Grossman, Robert G.; Powell, Suzanne; Lee, Dean; Ahmed, Nabil; Gottschalk, Stephen.

In: Molecular Therapy, Vol. 21, No. 3, 01.01.2013, p. 629-637.

Research output: Contribution to journalArticle

Chow, KKH, Naik, S, Kakarla, S, Brawley, VS, Shaffer, DR, Yi, Z, Rainusso, N, Wu, MF, Liu, H, Kew, Y, Grossman, RG, Powell, S, Lee, D, Ahmed, N & Gottschalk, S 2013, 'T cells redirected to EphA2 for the immunotherapy of glioblastoma', Molecular Therapy, vol. 21, no. 3, pp. 629-637. https://doi.org/10.1038/mt.2012.210
Chow KKH, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Molecular Therapy. 2013 Jan 1;21(3):629-637. https://doi.org/10.1038/mt.2012.210
Chow, Kevin KH ; Naik, Swati ; Kakarla, Sunitha ; Brawley, Vita S. ; Shaffer, Donald R. ; Yi, Zhongzhen ; Rainusso, Nino ; Wu, Meng Fen ; Liu, Hao ; Kew, Yvonne ; Grossman, Robert G. ; Powell, Suzanne ; Lee, Dean ; Ahmed, Nabil ; Gottschalk, Stephen. / T cells redirected to EphA2 for the immunotherapy of glioblastoma. In: Molecular Therapy. 2013 ; Vol. 21, No. 3. pp. 629-637.
@article{8f806957fca64da4880239eee0012552,
title = "T cells redirected to EphA2 for the immunotherapy of glioblastoma",
abstract = "Outcomes for patients with glioblastoma (GBM) remain poor despite aggressive multimodal therapy. Immunotherapy with genetically modified T cells expressing chimeric antigen receptors (CARs) targeting interleukin (IL)-13Rα2, epidermal growth factor receptor variant III (EGFRvIII), or human epidermal growth factor receptor 2 (HER2) has shown promise for the treatment of gliomas in preclinical models and in a clinical study (IL-13Rα2). However, targeting IL-13Rα2 and EGFRvIII is associated with the development of antigen loss variants, and there are safety concerns with targeting HER2. Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype. To generate EphA2-specific T cells, we constructed an EphA2-specific CAR with a CD28-ζ endodomain. EphA2-specific T cells recognized EphA2-positive glioma cells as judged by interferon-γ (IFN-γ) and IL-2 production and tumor cell killing. In addition, EphA2-specific T cells had potent activity against human glioma-initiating cells preventing neurosphere formation and destroying intact neurospheres in coculture assays. Adoptive transfer of EphA2-specific T cells resulted in the regression of glioma xenografts in severe combined immunodeficiency (SCID) mice and a significant survival advantage in comparison to untreated mice and mice treated with nontransduced T cells. Thus, EphA2-specific T-cell immunotherapy may be a promising approach for the treatment of EphA2-positive GBM.",
author = "Chow, {Kevin KH} and Swati Naik and Sunitha Kakarla and Brawley, {Vita S.} and Shaffer, {Donald R.} and Zhongzhen Yi and Nino Rainusso and Wu, {Meng Fen} and Hao Liu and Yvonne Kew and Grossman, {Robert G.} and Suzanne Powell and Dean Lee and Nabil Ahmed and Stephen Gottschalk",
year = "2013",
month = "1",
day = "1",
doi = "10.1038/mt.2012.210",
language = "English (US)",
volume = "21",
pages = "629--637",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - T cells redirected to EphA2 for the immunotherapy of glioblastoma

AU - Chow, Kevin KH

AU - Naik, Swati

AU - Kakarla, Sunitha

AU - Brawley, Vita S.

AU - Shaffer, Donald R.

AU - Yi, Zhongzhen

AU - Rainusso, Nino

AU - Wu, Meng Fen

AU - Liu, Hao

AU - Kew, Yvonne

AU - Grossman, Robert G.

AU - Powell, Suzanne

AU - Lee, Dean

AU - Ahmed, Nabil

AU - Gottschalk, Stephen

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Outcomes for patients with glioblastoma (GBM) remain poor despite aggressive multimodal therapy. Immunotherapy with genetically modified T cells expressing chimeric antigen receptors (CARs) targeting interleukin (IL)-13Rα2, epidermal growth factor receptor variant III (EGFRvIII), or human epidermal growth factor receptor 2 (HER2) has shown promise for the treatment of gliomas in preclinical models and in a clinical study (IL-13Rα2). However, targeting IL-13Rα2 and EGFRvIII is associated with the development of antigen loss variants, and there are safety concerns with targeting HER2. Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype. To generate EphA2-specific T cells, we constructed an EphA2-specific CAR with a CD28-ζ endodomain. EphA2-specific T cells recognized EphA2-positive glioma cells as judged by interferon-γ (IFN-γ) and IL-2 production and tumor cell killing. In addition, EphA2-specific T cells had potent activity against human glioma-initiating cells preventing neurosphere formation and destroying intact neurospheres in coculture assays. Adoptive transfer of EphA2-specific T cells resulted in the regression of glioma xenografts in severe combined immunodeficiency (SCID) mice and a significant survival advantage in comparison to untreated mice and mice treated with nontransduced T cells. Thus, EphA2-specific T-cell immunotherapy may be a promising approach for the treatment of EphA2-positive GBM.

AB - Outcomes for patients with glioblastoma (GBM) remain poor despite aggressive multimodal therapy. Immunotherapy with genetically modified T cells expressing chimeric antigen receptors (CARs) targeting interleukin (IL)-13Rα2, epidermal growth factor receptor variant III (EGFRvIII), or human epidermal growth factor receptor 2 (HER2) has shown promise for the treatment of gliomas in preclinical models and in a clinical study (IL-13Rα2). However, targeting IL-13Rα2 and EGFRvIII is associated with the development of antigen loss variants, and there are safety concerns with targeting HER2. Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype. To generate EphA2-specific T cells, we constructed an EphA2-specific CAR with a CD28-ζ endodomain. EphA2-specific T cells recognized EphA2-positive glioma cells as judged by interferon-γ (IFN-γ) and IL-2 production and tumor cell killing. In addition, EphA2-specific T cells had potent activity against human glioma-initiating cells preventing neurosphere formation and destroying intact neurospheres in coculture assays. Adoptive transfer of EphA2-specific T cells resulted in the regression of glioma xenografts in severe combined immunodeficiency (SCID) mice and a significant survival advantage in comparison to untreated mice and mice treated with nontransduced T cells. Thus, EphA2-specific T-cell immunotherapy may be a promising approach for the treatment of EphA2-positive GBM.

UR - http://www.scopus.com/inward/record.url?scp=84875215925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875215925&partnerID=8YFLogxK

U2 - 10.1038/mt.2012.210

DO - 10.1038/mt.2012.210

M3 - Article

VL - 21

SP - 629

EP - 637

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -